Baloxavir marboxil:the first anti-influenza drug targeting Cap-dependent endonuclease
Baloxavir marboxil is the first Cap-dependent endonuclease inhibitor,which inhibits the replication of influenza virus by inhibiting the activity of influenza RNA polymerase acidic protein subunit endonuclease.It was approved by the U.S.Food and Drug Administration in August 2022 for acute uncomplicated influenza patients aged 5 years and older with symptoms less than 48 hours.It was officially approved by the National Medical Products Administration of China in March 2023.Clinical trials have shown that baloxavir marboxil,with its advantages of single dose administration and high safety,may become an alternative for drug-resistant pediatric patients.
NETL
NSTL
万方数据
